Kersten Villringer Selected Research

Kersten Villringer Research Topics

14	Stroke (Strokes) 01/2021 - 01/2013
12	Ischemic Stroke 01/2021 - 01/2013
3	Ischemia 12/2023 - 01/2016
2	Infarction (Infarctions) 01/2020 - 01/2017
1	Retinal Artery Occlusion 12/2023
1	Vision Disorders (Hemeralopia) 12/2023
1	Tics (Tic) 01/2023
1	Parkinson Disease (Parkinson's Disease) 10/2021
1	Cognitive Dysfunction 10/2021
1	Inflammation (Inflammations) 01/2021
1	Dementia (Dementias) 01/2019
1	Hemorrhage 01/2018
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2018
1	Atrial Fibrillation 01/2018
1	Cerebral Infarction 01/2018
1	Cerebral Hemorrhage 01/2017

4	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2019 - 01/2013
2	Troponin T (Troponin T1)IBA 01/2019 - 04/2017
2	Contrast MediaIBA 01/2017 - 11/2015
1	Retinaldehyde (Retinal)IBA 12/2023
1	4- phenyl- 5,5- dicarbethoxy- 2- pyrrolidinoneIBA 10/2021
1	Metalloproteases (Metalloproteinases)IBA 01/2021
1	C-Reactive ProteinIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021
1	Vascular Endothelial Growth FactorsIBA 01/2021
1	deoxyhemoglobinIBA 01/2020
1	Oxygen (Dioxygen)IBA 01/2020
1	TroponinIBA 01/2019
1	Phenprocoumon (Liquamar)FDA Link 11/2018
1	Indicators and Reagents (Reagents)IBA 01/2017
1	GadoliniumIBA 01/2017
1	Glial Fibrillary Acidic ProteinIBA 01/2017
1	SteamIBA 01/2016
1	gadobutrolIBA 11/2015
1	cyclo(Arg-Pro) (CI 4)IBA 04/2014

5	Therapeutics 01/2020 - 01/2013
2	Contraindications 01/2015 - 04/2014
1	Patient Discharge 01/2023
1	Catheters 01/2018
1	Activities of Daily Living (ADL) 01/2018
1	Thrombolytic Therapy 06/2013
1	Aftercare (After-Treatment) 01/2013